1.
Massimo Breccia, Elisabetta Abruzzese, Alessandra Iurlo, Antonella Gozzini, Alessandro Isidori, Domenica Gangemi, Patrizia Pregno, Giuliana Alimena. Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. haematol [Internet]. 2016May31 [cited 2024Nov.24];101(6):e267-e268. Available from: https://haematologica.org/article/view/7759